Title:An Overview of Diabetic Cardiomyopathy
Volume: 20
Issue: 5
Author(s): Abdul Quaiyoom and Ranjeet Kumar*
Affiliation:
- Department of Pharmacy Practice, ISF College of Pharmacy, Moga, India
Keywords:
Diabetic cardiomyopathy, pathophysiology, complications, heart failure, diagnosis, coronary artery disease.
Abstract: Diabetic cardiomyopathy (DCM) is a myocardial disorder that is characterised by
structural and functional abnormalities of the heart muscle in the absence of hypertension, valvular
heart disease, congenital heart defects, or coronary artery disease (CAD). After witnessing a
particular form of cardiomyopathy in diabetic individuals, Rubler et al. came up with the moniker
diabetic cardiomyopathy in 1972. Four stages of DCM are documented, and the American
College of Cardiology/American Heart Association Stage and New York Heart Association
Class for HF have some overlap. Diabetes is linked to several distinct forms of heart failure.
Around 40% of people with heart failure with preserved ejection fraction (HFpEF) have diabetes,
which is thought to be closely associated with the pathophysiology of HFpEF. Diabetes and
HF are uniquely associated in a bidirectional manner. When compared to the general population
without diabetes, those with diabetes have a risk of heart failure that is up to four times higher. A
biomarker is a trait that is reliably measured and assessed as a predictor of healthy biological activities,
pathological processes, or pharmacologic responses to a clinical treatment. Several biomarker
values have been discovered to be greater in patients with diabetes than in control subjects
among those who have recently developed heart failure. Myocardial fibrosis and hypertrophy
are the primary characteristics of DCM, and structural alterations in the diabetic myocardium
are often examined by non-invasive, reliable, and reproducible procedures. An invasive
method called endomyocardial biopsy (EMB) is most often used to diagnose many cardiac illnesses.
